Skip to content
HowShorted

LENZ Therapeutics, Inc. short interest in 2023

In 2023, LENZ Therapeutics, Inc.'s disclosed short interest ran from 1.63% of shares outstanding on 13 Jan 2023 to 2.12% on 29 Dec 2023, a change of +0.49 percentage points. The year's high was 2.31% on 30 Nov 2023 and its low 1.16% on 31 May 2023, averaging 1.76% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.48 days on 31 Oct 2023. Full history: LENZ Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LENZ Therapeutics, Inc. in 2023

2023 in figures

Start of year
1.63% (13 Jan 2023)
End of year
2.12% (29 Dec 2023)
Change
+0.49 pp
High
2.31% (30 Nov 2023)
Low
1.16% (31 May 2023)
Average
1.76%
Highest days to cover
18.48 (31 Oct 2023)
SEC filings marked
5

Every report in 2023

LENZ Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20231.63%1.16
31 Jan 20231.38%5.61
15 Feb 20231.42%6.66
28 Feb 20231.74%2.17
15 Mar 20231.62%3.55
31 Mar 20231.51%11.0310-K filed, results (8-K)
14 Apr 20231.42%5.74
28 Apr 20231.26%3.43
15 May 20231.31%6.9210-Q filed
31 May 20231.16%8.00
15 Jun 20231.21%9.42
30 Jun 20231.89%2.47
14 Jul 20231.98%13.04
31 Jul 20231.97%11.88
15 Aug 20231.71%10.0710-Q filed
31 Aug 20231.83%8.19
15 Sep 20232.07%13.25
29 Sep 20232.21%6.63
13 Oct 20232.16%14.61
31 Oct 20232.12%18.48
15 Nov 20232.12%6.0910-Q filed
30 Nov 20232.31%14.78
15 Dec 20232.17%4.99
29 Dec 20232.12%4.54

See also: LENZ Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.